Myriad Genetics, Inc. (MYGN) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $3.97 (+2.19%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 24, 2026 | Lu Li | UBS | $6.00 | +51.1% |
| Nov 4, 2025 | Lu Li | UBS | $8.00 | +101.5% |
| May 7, 2025 | Bill Bonello | Craig-Hallum | $18.00 | +353.4% |
| May 7, 2025 | Lu Li | UBS | $7.00 | +76.3% |
| May 7, 2025 | Brandon Couillard | Wells Fargo | $6.00 | +51.1% |
| Dec 9, 2024 | Puneet Souda | Leerink Partners | $21.00 | +429.0% |
| Oct 14, 2024 | Sung Ji Nam | Scotiabank | $34.00 | +756.4% |
| Sep 19, 2024 | Tejas Savant | Morgan Stanley | $32.00 | +706.0% |
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $35.00 | +781.6% |
| Aug 7, 2024 | Subbu Nambi | Guggenheim | $29.00 | +630.5% |
| Jun 26, 2024 | Sung Ji Nam | Scotiabank | $29.00 | +630.5% |
| May 13, 2024 | Jon Peterson | Piper Sandler | $28.00 | +605.3% |
| Dec 21, 2023 | David Westenberg | Piper Sandler | $23.00 | +479.3% |
| Oct 5, 2022 | Mason Carrico | Stephens | $22.00 | +454.2% |
Top Analysts Covering MYGN
MYGN vs Sector & Market
| Metric | MYGN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.14 | 2.25 | 2.42 |
| Analyst Count | 7 | 8 | 18 |
| Target Upside | -13.7% | +16187.3% | +19.5% |
| P/E Ratio | -1.23 | 3.79 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $863M | $864M | $866M | 8 |
| 2027-03-31 | $212M | $214M | $216M | 3 |
| 2027-06-30 | $225M | $227M | $229M | 3 |
| 2027-09-30 | $232M | $235M | $237M | 3 |
| 2027-12-31 | $237M | $239M | $241M | 3 |
| 2028-03-31 | $223M | $225M | $227M | 2 |
| 2028-06-30 | $236M | $238M | $240M | 2 |
| 2028-09-30 | $241M | $244M | $246M | 2 |
| 2028-12-31 | $247M | $250M | $252M | 2 |
| 2029-12-31 | $995M | $1.00B | $1.02B | 5 |
| 2030-12-31 | $1.03B | $1.04B | $1.05B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.04 | $0.03 | $0.13 | 6 |
| 2027-03-31 | $-0.02 | $-0.02 | $-0.02 | 2 |
| 2027-06-30 | $0.03 | $0.03 | $0.03 | 2 |
| 2027-09-30 | $0.06 | $0.06 | $0.06 | 2 |
| 2027-12-31 | $0.06 | $0.06 | $0.06 | 2 |
| 2028-03-31 | $-0.00 | $-0.00 | $-0.00 | 3 |
| 2028-06-30 | $0.07 | $0.07 | $0.07 | 3 |
| 2028-09-30 | $0.06 | $0.06 | $0.06 | 3 |
| 2028-12-31 | $0.06 | $0.06 | $0.06 | 3 |
| 2029-12-31 | $0.47 | $0.48 | $0.48 | 1 |
| 2030-12-31 | $0.61 | $0.62 | $0.63 | 1 |
Frequently Asked Questions
What is the analyst consensus for MYGN?
The consensus among 7 analysts covering Myriad Genetics, Inc. (MYGN) is Hold with an average price target of $6.00.
What is the highest price target for MYGN?
The highest price target for MYGN is $35.00, set by Brandon Couillard at Wells Fargo on 2024-08-27.
What is the lowest price target for MYGN?
The lowest price target for MYGN is $6.00, set by Brandon Couillard at Wells Fargo on 2025-05-07.
How many analysts cover MYGN?
7 analysts have issued ratings for Myriad Genetics, Inc. in the past 12 months.
Is MYGN a buy or sell right now?
Based on 7 analyst ratings, MYGN has a consensus rating of Hold (3.14/5) with a -13.7% upside to the consensus target of $6.00.
What are the earnings estimates for MYGN?
Analysts estimate MYGN will report EPS of $0.03 for the period ending 2026-12-31, with revenue estimated at $864M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.